S
Seock-Ah Im
Researcher at Seoul National University Hospital
Publications - 655
Citations - 37014
Seock-Ah Im is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 70, co-authored 563 publications receiving 26433 citations. Previous affiliations of Seock-Ah Im include Seoul National University & Sungkyunkwan University.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga,Javier Cortes,Sung-Bae Kim,Seock-Ah Im,Roberto Hegg,Young-Hyuck Im,L Roman,Jose Luiz Pedrini,Tadeusz Pienkowski,Adam Knott,Emma Clark,Mark C. Benyunes,Graham Ross,Sandra M. Swain +13 more
TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
Journal ArticleDOI
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne Armstrong,Wenting Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.
Journal ArticleDOI
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.
Journal ArticleDOI
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn,Miguel Martin,Hope S. Rugo,Stephen R. Jones,Seock-Ah Im,Karen A. Gelmon,Nadia Harbeck,Oleg Lipatov,Janice M. Walshe,Stacy L. Moulder,Eric Gauthier,Dongrui R. Lu,Sophia Randolph,Véronique Diéras,Dennis J. Slamon +14 more
TL;DR: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with let rozole alone, although the rates of myelotoxic effects were higher with palbokiclib-letrozoles.
Journal ArticleDOI
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli,Nicholas C. Turner,Igor Bondarenko,Jungsil Ro,Seock-Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Ke Zhang,Kathy Puyana Theall,Yuqiu Jiang,Cynthia Huang Bartlett,Maria Koehler,Dennis J. Slamon +17 more
TL;DR: This study aimed to confirm the earlier findings with this extended follow-up and show the results for subgroup and biomarker analyses, and assesses endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline.